Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Leamon

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Molecular Medicine (Cambridge, Mass.)|July 17, 2015
Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor EverolimusYingjuan Lu, Nikki Parker, Paul J Kleindl, et al.
Cell Reports. Medicine|November 10, 2021
Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causesYingjuan J Lu, Leroy W Wheeler, Haiyan Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancerR Wendel Naumann, Robert L Coleman, Robert A Burger, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Molecular Medicine (Cambridge, Mass.)|July 17, 2015
Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor EverolimusYingjuan Lu, Nikki Parker, Paul J Kleindl, et al.
Cell Reports. Medicine|November 10, 2021
Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causesYingjuan J Lu, Leroy W Wheeler, Haiyan Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancerR Wendel Naumann, Robert L Coleman, Robert A Burger, et al.
Pageof 8